Investors Overview

Investors Overview

Our Mission

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care.

Learn more about BD

News Releases

01/25/2021

Summary Toggle New Clinical Data Shows BD Antigen Test May Be More Selective In Detecting Infectious COVID-19 Patients Than Molecular Tests

Peer-Reviewed Study Suggests BD Antigen Test Likely to Be More Selective at Detecting Patients Who Are Shedding Infectious SARS-CoV-2 Virus FRANKLIN LAKES, N.J. , Jan. 25, 2021 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, today

PDF Version
01/12/2021

Summary Toggle BD Provides Updates To Its Fiscal 2021 Financial Outlook And Intends To Comment On Its Preliminary First Fiscal Quarter Revenue Performance During Today's Webcast At The 39th Annual J.P. Morgan Healthcare Conference

- Preliminary first fiscal quarter 2021 revenues of $5.3 billion grew 25.6% on a reported basis. On a currency-neutral basis, revenues increased 24.2%, driven by higher base revenues in all three segments and COVID diagnostic revenues. - BD's estimated COVID-19 testing sales of approximately $865

PDF Version 181.6 KB
12/22/2020

Summary Toggle BD to Present at the 39th Annual J.P. Morgan Healthcare Conference

FRANKLIN LAKES, N.J. , Dec. 22, 2020 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 39 th Annual J.P. Morgan Healthcare Conference via webcast.

PDF Version
12/16/2020

Summary Toggle BD Surpasses 1 Billion Injection Device Orders in Support of COVID-19 Vaccination Efforts Around the World

FRANKLIN LAKES, N.J. , Dec. 16, 2020 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling more than 1 billion injection devices to support global COVID-19

PDF Version
12/09/2020

Summary Toggle New Clinical Trial Data Demonstrates BD Libertas™ Wearable Injector as a Drug Delivery System

FRANKLIN LAKES, N.J. , Dec. 9, 2020 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, today announced publication of the results from a 52-subject human clinical trial with the BD Libertas™ Wearable Injector.

PDF Version
12/02/2020

Summary Toggle BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years

Investment includes new manufacturing facility in Europe FRANKLIN LAKES, N.J. , Dec. 2, 2020 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, today announced plans to invest approximately $1.2 billion over a 4-year period to expand and

PDF Version